Noor Malik
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (16)
Year:
2026
Background While serial sampling of glioma tissue is rarely performed prior to recurrence, cerebrospinal fluid (CSF) is an underutilized longitudinal source of candidate glioma biomarkers for understanding therapeutic impacts. However, the impact of key variables to consider in longitudinal CSF samples for monitoring biomarker discovery, including anatomical location and post-surgical changes, remains unknown. Methods Aptamer-based proteomics was performed on 147 CSF samples from 74 patients; 71 of whom had grade 2–4 astrocytomas or grade 2–3 oligodendrogliomas. This included pre- versus post-resection intracranial CSF samples obtained at early (1–16 days; n = 20 patients) or delayed (86–153 days; n = 11 patients) time points for patients with glioma. Paired lumbar versus intracranial glioma CSF samples were also obtained (n = 14 patients). Results Significant differences were identified in the CSF proteome between lumbar, subarachnoid, and ventricular CSF in patients with gliomas. Importantly, we found that resection had a significant, evolving longitudinal impact on the CSF proteome, with distinct sets of proteins present at different time points since resection. Our analysis of serial intracranial CSF samples suggests the early potential for disease monitoring and evaluation of pharmacodynamic impact of targeted therapies, such as bevacizumab and immunotherapies. Conclusions The intracranial glioma CSF proteome serves as a rich and dynamic reservoir of potential biomarkers that can be used to evaluate the effects of resection and other therapies over time. All data within this study, including detailed individual clinical annotations, are shared as a resource for the neuro-oncology community to collectively address these unanswered questions and further understand glioma biology through CSF proteomics.
Year:
2025
Purpose: Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients with gliomas. Experimental Design: Adults with gliomas underwent longitudinal intracranial CSF collection via Ommaya reservoirs or ventriculoperitoneal shunts. Cell-free DNA (cfDNA) was extracted and analyzed using PredicineCARE for cancer variant profiling and/or PredicineSCORE for low-pass whole-genome sequencing. Results: Five patients (two females and three males; median age, 40 years; range, 32–64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n = 4) or ventriculoperitoneal shunts (n = 1). In total, 47 CSF samples were obtained (median volume, 4.00 mL; 0.5–5 mL). Forty-one samples (87.2%) yielded sufficient cfDNA for testing. Patient-specific tumor-associated variant allelic frequencies (VAF), and thus tumor fraction, decreased in pre- versus postchemoradiation samples, including through pseudoprogression. These also increased with radiographic progression in three patients, although identifying the time of definitive disease progression from MRIs was a significant limitation. In two patients with isocitrate dehydrogenase (IDH)–mutant gliomas, decreasing IDH1 VAF after resection and chemoradiation correlated with decreased CSF D-2-hydroxyglutarate levels (0.64× and 0.62×, respectively, for the first patient and 0.01× and 0.07× for the other patient), although D-2-hydroxyglutarate and IDH1 VAF were not concordant in one patient thereafter. Moreover, the copy-number burden decreased below the limit of quantification during treatment and increased above the limit at progression. Conclusions: Longitudinal intracranial CSF cfDNA can be obtained in patients with gliomas during their disease course. However, before deploying this technique, numerous questions and challenges should be answered.
Year:
2025
OBJECTIVE Despite advancements in therapy and improved survival rates for patients with primary central nervous system lymphoma (PCNSL), the optimal management strategy for recurrent or refractory PCNSL (r/r PCNSL) remains undefined. In such cases, repeat brain biopsy is often performed to confirm disease recurrence, though its diagnostic and therapeutic value is uncertain. This study evaluates whether repeat brain biopsy provides new, actionable diagnostic insights that influence treatment decisions. METHODS A retrospective analysis was conducted on patients with a confirmed diagnosis of PCNSL who underwent repeat brain biopsy for suspected recurrent or refractory disease between 2005 and 2023. Patients with a history of other CNS neoplasms, demyelinating disorders, or active systemic disease were excluded. RESULTS Twenty patients met inclusion criteria (55% female), with a mean age at biopsy of 56 years in the PCNSL group and 61 years in the r/r PCNSL group. While the overall distribution of presenting symptoms did not significantly differ (p = 0.2), gait instability, weakness, and cognitive decline were more common in r/r PCNSL. PCNSL more often presented with single lesions, while r/r PCNSL had predominantly multiple lesions (p < 0.05). Periventricular enhancement was significantly more frequent in r/r PCNSL (p < 0.05), though other radiologic features were comparable. Repeat biopsy confirmed DLBCL in 90% of cases; no infections or alternate malignancies were identified. Diagnostic clarification was the primary indication for repeat biopsy. Chemotherapy regimens were altered in 50% of post-biopsy cases, without a corresponding difference in overall survival (p = 0.79). Procedure-related morbidity was observed in three patients (15%). CONCLUSIONS The second biopsy in most cases reaffirmed the original diagnosis of diffuse large B cell lymphoma. Although biopsy results led to treatment adjustments; these changes did not affect overall survival.
Year:
2025
BACKGROUND Gliomas account for the majority of malignant brain tumors. Prognostication currently relies on molecular markers such as isocitrate dehydrogenase (IDH) mutation and O6-methylguanine-DNA methyltransferase (MGMT) methylation. More recently, lactate dehydrogenase (LDH) has shown promising results to be used as a laboratory marker to predict prognosis in patients with tumors, which leads to the question of whether it can perform a similar role in glioma prognosis. Despite growing interest, a comprehensive synthesis of the literature is lacking. METHODS A systematic review was conducted following the PRISMA 2020 guidelines. Searches were performed across of PubMed/MEDLINE, Scopus, and Cochrane Library databases from inception through April 15, 2025, using a predefined search strategy. Two independent reviewers screened 1,350 articles with disagreements resolved by a third. RESULTS Eight studies were included, covering 1,908 glioma cases. LDH cutoff values for risk stratification ranged mainly between 170 and 300 U/L. Elevated LDH levels correlated with more aggressive tumor subtypes, especially high-grade gliomas, and were independently predictive of decreased overall survival and progression-free survival across multiple cohorts with hazard ratios commonly ranging from 1.4 to >2.0 after adjustment for confounders such as age and performance status. Median OS differences between high and low LDH groups ranged from 5 to 11 months. Receiver operating characteristic (ROC) analyses demonstrated moderate predictive accuracy for LDH levels, with area under the curve (AUC) values typically between 0.60 and 0.74. Some studies integrated LDH into prognostic scoring systems that effectively stratified patients by survival risk. CONCLUSIONS This review offers comprehensive overview of LDH s a prognostic biomarker in glioma patients. LDH appears to correlate with tumor aggressiveness and clinical outcomes and may serve as a cost-effective, accessible adjunct to current prognostic models in neuro-oncology
Year:
2025
BACKGROUND Metastatic brain tumors (MBTs) are more common than primary brain tumors and associated with poor survival. This study examined whether race × income interaction predicts differences in treatment receipt and survival among patients with MBTs from lung, breast, melanoma, and prostate cancer METHODS We analyzed SEER data from 2010–2022, identifying adults with MBTs from lung, melanoma, breast, and prostate primaries. Treatment outcomes included receipt of chemotherapy, radiation, or surgery, and the sequence of radiation or chemotherapy relative to surgery. Survival outcomes were modeled using Cox proportional hazards regression. Unadjusted, adjusted, and interaction models (race and income) were run separately for each cancer type. Income was binarized into low and high using a cutoff of $75,000. RESULTS A total of 77,895 patients were included (69,928 lung, 3,786 melanoma, 3,588 breast, 593 prostate). Mean age was 65 years (SD 5 years), 71% were White, and 40% fell into the low-income category. In the adjusted survival model, Hispanic and Asian lung cancer patients showed improved survival compared to White patients (HR 0.93 and 0.71, CI 0.93–0.96 and 0.68–0.72, respectively, p <.001), while low-income patients had worse outcomes (HR 1.66, CI 1.14–1.18, p <.001). After interaction modeling, low-income Black patients with lung cancer had a survival advantage over low-income White patients (HR 0.92, CI 0.87–0.97, p =.001), while Asian and Hispanic patients maintained their survival advantage regardless of income. Black patients with breast MBTs experienced persistently worse survival, regardless of model (HR 1.19, CI 1.02–1.38, p =.019). CONCLUSIONS Income modifies the effect of race on survival in patients with MBTs, challenging past assumptions that race alone predicts poorer outcomes. Findings suggest that survival disparities may be driven more by socioeconomic conditions than differential treatment access.
Year:
2025
Purpose: Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients with gliomas. Experimental Design: Adults with gliomas underwent longitudinal intracranial CSF collection via Ommaya reservoirs or ventriculoperitoneal shunts. Cell-free DNA (cfDNA) was extracted and analyzed using PredicineCARE for cancer variant profiling and/or PredicineSCORE for low-pass whole-genome sequencing. Results: Five patients (two females and three males; median age, 40 years; range, 32–64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs ( n = 4) or ventriculoperitoneal shunts ( n = 1). In total, 47 CSF samples were obtained (median volume, 4.00 mL; 0.5–5 mL). Forty-one samples (87.2%) yielded sufficient cfDNA for testing. Patient-specific tumor-associated variant allelic frequencies (VAF), and thus tumor fraction, decreased in pre- versus postchemoradiation samples, including through pseudoprogression. These also increased with radiographic progression in three patients, although identifying the time of definitive disease progression from MRIs was a significant limitation. In two patients with isocitrate dehydrogenase ( IDH )–mutant gliomas, decreasing IDH1 VAF after resection and chemoradiation correlated with decreased CSF D-2-hydroxyglutarate levels (0.64× and 0.62×, respectively, for the first patient and 0.01× and 0.07× for the other patient), although D-2-hydroxyglutarate and IDH1 VAF were not concordant in one patient thereafter. Moreover, the copy-number burden decreased below the limit of quantification during treatment and increased above the limit at progression. Conclusions: Longitudinal intracranial CSF cfDNA can be obtained in patients with gliomas during their disease course. However, before deploying this technique, numerous questions and challenges should be answered.
Year:
2025
IMPORTANCE Current methods for glioma treatment response assessment are limited. Intracranial cerebrospinal fluid (CSF) may provide a previously untapped source of longitudinal biomarkers, such as cell-free DNA (cfDNA), for disease monitoring. OBJECTIVE To assess the feasibility of obtaining longitudinal intracranial CSF cfDNA from patients with gliomas during their disease course. DESIGN This case series was initiated in 2021, with patients followed until last clinical follow-up (death or present time). SETTING This single-center study was conducted at a large academic medical center. PARTICIPANTS Adults with gliomas were recruited for longitudinal intracranial CSF collection using 1) Ommaya reservoirs, from which CSF would be sampled on at least two separate occasions, or 2) CSF collection from other clinically indicated CSF access devices, such as ventriculoperitoneal (VP) shunts. INTERVENTIONS CSF was collected from Ommaya reservoirs in four patients and from an existing VP shunt in one patient. MAIN OUTCOMES AND MEASURES The study aimed to collect CSF for biobanking and biomarker discovery, with the hypothesis that CSF could serve as a source of longitudinally acquirable biomarkers. RESULTS Five patients (2 females, 3 males; median: 40 years, range 32-64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n=4/5 patients) or VP shunt (n=1/5). Three patients had glioblastoma and two had astrocytoma, IDH-mutant, grade 4. In total, thirty-five CSF samples were obtained (median: 3.80 mL; 0.5-5 mL), with 30 (85.7%) yielding sufficient cfDNA for Next-Generation Sequencing (n=28) or Low-Pass Whole Genome sequencing (all samples). Tumor fraction was found to increase with radiographic progression. Changes in variant allelic frequencies (VAFs) may be seen within individual patients after resection and chemoradiation. In two patients, changes in tumor-specific IDH1 VAF correlated with CSF D-2-hydroxyglutarate levels, the oncometabolite of IDH mutant tumors. Copy number burden (CNB) decreased below the limit of quantification during treatment. CONCLUSIONS AND RELEVANCE Longitudinal CSF cfDNA can feasibly be obtained via CSF access devices in patients with gliomas during their disease course. Ongoing studies will evaluate hypotheses generated in this case series regarding how longitudinal CSF cfDNA could be utilized to sensitively detect changes in disease burden. Trial Registration NCT04692324 https://clinicaltrials.gov/study/NCT04692324 ; NCT04692337 https://clinicaltrials.gov/study/NCT04692337 QUESTION What is the feasibility of obtaining longitudinal intracranial cerebrospinal fluid cell-free DNA from patients with high-grade gliomas to evaluate changes during treatment? FINDING In this case series, we find that CSF cfDNA can feasibly be obtained throughout treatment via CSF access devices. We find that changes in tumor fraction or tumor-associated variant allele frequencies (VAFs) may correlate with disease trajectory, with VAFs positively correlating to other tumor-associated candidate biomarkers. MEANING Longitudinal cerebrospinal cell-free DNA may inform the impact of treatment throughout a specific patient’s disease course, from the time of resection through radiographic progression.
Year:
2024
Improved response assessment methods are needed for patients with gliomas. Intracranial cerebrospinal fluid (CSF) is longitudinally accessible and provides an abundance source of candidate biomarkers, such as cell-free DNA (cfDNA), for disease monitoring. To evaluate the clinical feasibility of molecular profiling from longitudinal intracranial CSF, CSF was acquired from patients with CSF access devices, including Ommaya reservoirs and ventriculoperitoneal shunts. cfDNA was extracted and analyzed via PredicineCARE (Next Generation sequencing) or PredicineSCORE (low pass whole genome sequencing). Five patients (2 females, 3 males; median age: 40 years, range 32-64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n=4) or VP shunt (n=1). In total, forty-eight CSF samples were obtained (median volume: 4.00 mL; 0.5-5 mL), with 39 samples (81.3%) yielding sufficient cfDNA for variant profiling. Our initial findings suggest that tumor fraction increased by 6.28x, 2.87x, and 8.31x with radiographic progression in three patients. Tumor fraction decreased by 0.08x and 0.04x in two patients with paired immediate pre-versus-post chemoradiation samples. Despite ongoing pseudoprogression in one patient, tumor fraction decreased to unmeasurable levels from a post-resection baseline of 0.26. Patient-specific tumor-associated variant allelic frequencies (VAFs), including TP53, PTEN, TERT, and CDKN2A/B, decreased within individual patients after resection and chemoradiation. In two patients with isocitrate dehydrogenase (IDH) mutant gliomas, decreasing IDH1 VAF after resection and chemoradiation correlated with decreased CSF D-2-hydroxyglutarate (D-2-HG) levels (0.64x and 0.62x, respectively, for the first patient, and 0.01x and 0.07x for the other patient). Both CSF IDH1 VAF and CSF D-2-HG increased a patient who had radiographic progression (2.56x and 9.21x, respectively). Moreover, CNB decreased below the limit of quantification during treatment and increased above the limit at progression. In conclusion, longitudinal CSF cfDNA can feasibly be obtained via CSF access devices in patients with gliomas during their disease course toward evaluating candidate monitoring biomarkers.
Year:
2024
While serial sampling of glioma tissue is rarely performed before recurrence, cerebrospinal fluid (CSF) can be acquired serially to evaluate candidate monitoring and pharmacodynamic biomarkers in patients with gliomas. However, the impact of key variables to consider in longitudinal CSF, including anatomical location and post-surgical changes, remains unknown. To that end, pre- versus post-resection intracranial CSF samples from patients with gliomas were obtained at early (1-16 days; n=20) or delayed (86-153 days; n=11) timepoints, as well as lumbar-versus-intracranial glioma CSF samples (n=14). Using aptamer-based proteomics, we identified significant differences in the glioma CSF proteome between lumbar, subarachnoid, and ventricular CSF. Indeed, intracranial CSF in paired lumbar/intracranial samples had nearly 1600 unique aptamers, regardless of which intracranial location was compared to the paired lumbar CSF, including in enrichment style analyses that evaluated the overlap between protein states. Importantly, resection had a significant, evolving longitudinal impact on the CSF proteome, with subsets of proteins associated with early versus delayed post-resection changes, many of which were enriched for inflammatory-related pathways. Interestingly, despite increased contamination from surgical debris, enrichment for plasma-associated proteins decreased with resection (FDR: 0.000), suggesting that a portion of the baseline glioma panel could be derived from plasma-originating analytes due to blood-brain barrier disruption. Despite these challenges, our data still revealed preliminary candidate monitoring biomarkers, such as brevican, that increased with progression (example patient: fold-change of 3.58x and 2.08x through lomustine and bevacizumab, respectively), but not pseudoprogression (Fold change less than 1.5). Serial intracranial CSF samples suggested the early potential for disease monitoring and evaluation of pharmacodynamic impact of targeted therapies, including bevacizumab and pembrolizumab. In conclusion, our available data to date suggest that the intracranial glioma CSF proteome provides an abundant and evolving source of candidate biomarkers to longitudinally discern the impact of resection and systemic treatments.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (4)
Timothy Kaufmann
Associate Professor
Mayo Clinic Minnesota
Ignacio Jusue-Torres
Northwestern Medicine
Ugur Sener
Associate Professor of Neurology
Mayo Clinic
Burns Terry
Assistant Professor
Mayo Clinic Rochester
Make your next move.
Prepare your application
Review drafts before you send them.